Eastwood Bio-Medical Canada Inc.
EWOOF · OTC
10/31/2023 | 10/31/2022 | 10/31/2021 | 10/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.13 | 9.73 | 5.94 | -1.30 |
| FCF Yield | -0.01% | -0.01% | -0.12% | -0.52% |
| EV / EBITDA | -279.45 | -3,487.40 | -210.12 | -139.41 |
| Quality | ||||
| ROIC | 64.87% | 55.76% | 527.45% | -176.55% |
| Gross Margin | 63.18% | 69.45% | 46.72% | 25.00% |
| Cash Conversion Ratio | 0.03 | 0.03 | 0.19 | 0.64 |
| Growth | ||||
| Revenue 3-Year CAGR | -4.00% | 21.86% | -0.02% | 8.32% |
| Free Cash Flow Growth | -131.37% | 94.01% | 77.56% | -255.22% |
| Safety | ||||
| Net Debt / EBITDA | -0.11 | -0.69 | -0.02 | 0.13 |
| Interest Coverage | -17.94 | -12.08 | -213.72 | -358.82 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -81.38 | -51.35 | -34.77 | -35.34 |